CD38 and cancer: These recent findings suggest that silencing CD38 (through methylation) may confer survival advantage to tumor-initiating progenitor cells or proliferative cancer cells by increasing NAD+ availability and mitochondrial function (Chiarugi et al., 2012; Camacho-Pereira et al., 2016; Liu et al., 2016; Chmielewski et al., 2018; Mottahedeh et al., 2018).